Explain the classes of oral hypoglycemic agents, including their mechanisms of action and associated side effects.

Oral Hypoglycemic Agents by Class

Oral hypoglycemic agents are organized into six major classes, each with distinct mechanisms of action and side effect profiles that should guide selection based on patient-specific factors including cardiovascular disease, kidney function, hypoglycemia risk, and weight considerations.

1. Biguanides (Metformin)

Mechanism of Action

Metformin decreases hepatic glucose output and enhances insulin sensitivity primarily in the liver and muscle without directly affecting β-cell function 1.

Efficacy

• Reduces HbA1c by approximately 1.0-1.5% 2
• Metformin remains the first-line medication for type 2 diabetes management due to its high efficacy, good safety profile, and low cost 2

Side Effects

• Gastrointestinal disturbances (most common): abdominal discomfort, diarrhea, nausea 1
• Vitamin B12 deficiency with long-term use—periodic monitoring recommended 3, 2
• Rare lactic acidosis (usually in setting of severe illness or acute kidney injury) 2, 4
• Weight neutral or modest weight loss 1
• No hypoglycemia risk when used as monotherapy 1

Key Contraindications & Precautions

• Contraindicated: eGFR <30 mL/min/1.73 m², impaired hepatic function, hypoxemic conditions, severe infections, alcohol abuse 1, 3
• Use lower doses if eGFR 30-45 mL/min/1.73 m² 3
• Temporarily discontinue before procedures with iodinated contrast, during hospitalizations, or acute illness that may compromise renal/liver function 1, 3
• Gradually titrate dose to minimize GI side effects 5

---

2. Sulfonylureas

Mechanism of Action

Stimulate insulin secretion from pancreatic β-cells in a glucose-independent manner 1, 2, 6.

Examples

Glipizide, glimepiride, gliclazide, glyburide (avoid in elderly), tolazamide, tolbutamide 1, 2

Efficacy

• High glucose-lowering efficacy: reduce HbA1c by 1.5-2% 2, 6, 7
• Inexpensive and widely available 2
• Demonstrated reduction in microvascular complications in UKPDS and ADVANCE trials 2

Side Effects

• Hypoglycemia (major concern)—risk highest with glyburide; lower with glipizide, glimepiride, gliclazide 2, 3
• Weight gain (relatively modest in large cohorts) 2
• Bone loss and increased fracture risk 3
• Lack of durable glycemic effect over time 2
• Drug interactions: many antimicrobials (fluoroquinolones, sulfamethoxazole-trimethoprim) increase effective dose and precipitate hypoglycemia 3

Key Precautions

• Use shorter-acting agents (glipizide) in elderly; avoid glyburide 3
• When combined with other agents (DPP-4 inhibitors, GLP-1 RAs), hypoglycemia risk increases 50% 2
• Monitor hypoglycemia frequency at each visit 3

---

3. Meglitinides (Glinides)

Mechanism of Action

Non-sulfonylurea insulin secretagogues that promote short-term, glucose-stimulated insulin secretion 1, 7.

Examples

Repaglinide, nateglinide, mitiglinide 1, 7

Efficacy

• Reduce HbA1c by 0.5-1.5% 7
• Particularly effective for postprandial glucose control 7

Side Effects

• Hypoglycemia (lower risk than sulfonylureas) 7
• Weight gain 7

Key Features

• Must be taken immediately before meals 1, 7
• Can be used in patients with renal insufficiency 7

---

4. Thiazolidinediones (TZDs)

Mechanism of Action

Selective peroxisome proliferator-activated receptor-γ agonists that increase insulin sensitivity in peripheral tissues 2, 6, 7.

Examples

Pioglitazone, rosiglitazone (use declined after 2007 due to cardiovascular concerns) 6

Efficacy

• High glucose-lowering efficacy: reduce HbA1c by 1.0-1.6% 2, 6
• Best evidence for glycemic durability among glucose-lowering medications 2
• Increase HDL-cholesterol 2
• Pioglitazone may reduce cardiovascular endpoints 2

Side Effects

• Fluid retention and congestive heart failure (black box warning) 2, 6
• Weight gain (mitigated by lower doses like pioglitazone 15-30 mg) 2
• Bone fractures (especially in premenopausal and postmenopausal women) 6
• Decreased bone mineral density at lumbar spine, hip, and radius 6
• Possible bladder cancer risk 2
• Edema 2

Key Contraindications

• Heart failure (NYHA class II and above) 3, 6, 7
• Active liver disease or transaminase elevations >2.5× upper limit of normal 7
• Severe osteoporosis and fractures 7

Precautions

• Use with extreme caution in elderly, especially those on insulin or at risk for heart failure, fractures, or macular edema 3
• Monitor bone health, especially in women 6

---

5. α-Glucosidase Inhibitors

Mechanism of Action

Slow hydrolysis of complex carbohydrates and delay carbohydrate absorption in the upper small intestine 1, 7.

Examples

Acarbose, miglitol, voglibose 1, 7

Efficacy

• Reduce HbA1c by approximately 0.5-1.0% 7
• Particularly effective for postprandial hyperglycemia 7

Side Effects

• Gastrointestinal reactions: abdominal distension, flatulence (most common) 7
• Very low hypoglycemia risk when used alone 7

Key Features

• Take at start of meal for maximal effect 5
• Start with small dose and gradually increase to reduce adverse effects 7
• If hypoglycemia occurs while on combination therapy, must use monosaccharides (glucose tablets) for treatment—drug prevents digestion of polysaccharides 5

---

6. DPP-4 Inhibitors (Dipeptidyl Peptidase-4 Inhibitors)

Mechanism of Action

Increase insulin secretion and reduce glucagon secretion in a glucose-dependent manner 2.

Examples

Saxagliptin, alogliptin, sitagliptin, linagliptin 2

Efficacy

• Moderate glucose-lowering efficacy: reduce HbA1c by approximately 0.7-1.0% 2, 6

Side Effects

• Well tolerated overall 2
• Weight neutral 2
• Minimal hypoglycemia risk as monotherapy 2, 3
• When added to sulfonylurea, hypoglycemia risk increases 50% 2
• Rare: pancreatitis, musculoskeletal side effects, arthralgia 2, 6
• Heart failure concerns with saxagliptin and alogliptin 2

Key Features

• Dose adjustment required based on renal function (except linagliptin, which has minimal renal excretion) 2
• CVOTs showed cardiovascular safety but no cardiovascular benefit 2
• Cost may be barrier for some patients 3

---

Clinical Selection Algorithm

Based on the 2018 ADA/EASD Consensus Report 2 and 2025 ADA Standards 3, 8:

First-Line Therapy

• Metformin unless contraindicated (renal dysfunction, hepatic disease, severe illness) 1, 2

Second-Line Therapy Selection

Prioritize based on comorbidities:

1. If established ASCVD, heart failure, or CKD present: Add SGLT2 inhibitor or GLP-1 RA (note: these are injectable, not oral agents, but take priority) 8

2. If no cardiovascular/renal disease, select based on:

   • Minimize hypoglycemia risk: DPP-4 inhibitors, TZDs (with caution), α-glucosidase inhibitors 2
   • Minimize weight gain: DPP-4 inhibitors, α-glucosidase inhibitors 2
   • Cost considerations: Sulfonylureas (but accept hypoglycemia and weight gain risks) 2
   • Glycemic durability: TZDs (but accept safety concerns) 2

Special Populations

Elderly patients 3:

• Avoid glyburide (long-acting sulfonylurea)
• Use glipizide if sulfonylurea needed
• TZDs: use with extreme caution due to heart failure, fracture, and fluid retention risks
• Metformin: safe if eGFR >30 mL/min/1.73 m²; monitor renal function every 3-6 months

Renal impairment:

• Metformin: contraindicated if eGFR <30; lower dose if eGFR 30-45 3
• DPP-4 inhibitors: dose adjustment required (except linagliptin) 2
• Glinides: can be used 7

Obese/insulin-resistant patients:

• Prefer metformin, TZDs (if no contraindications) 9
• Avoid sulfonylureas due to weight gain 2

---

Critical Pitfalls to Avoid

1. Never combine GLP-1 RAs with DPP-4 inhibitors—no added benefit 8
2. Glyburide in elderly—highest hypoglycemia risk among sulfonylureas 3
3. TZDs in heart failure patients—black box warning 2, 6, 7
4. Metformin without monitoring renal function—risk of lactic acidosis 1, 3, 2
5. Treating hypoglycemia with complex carbohydrates in patients on α-glucosidase inhibitors—use glucose tablets instead 5
6. Continuing metformin during acute illness, dehydration, or before contrast studies—temporarily discontinue 1, 3, 2
7. Ignoring drug interactions with sulfonylureas—fluoroquinolones and sulfamethoxazole-trimethoprim increase hypoglycemia risk 3